PTAFR and pancreatic neoplasm: Similar to our studies that only PANC-1 cells, but not Hs766T cells, were able to release MVPs in response to gemcitabine, it is possible that some of the pancreatic cancer cells which exhibited increased sensitivity to gemcitabine-mediated MVP release in this study [41], were PAF-R-expressing, and others showing less sensitivity to gemcitabine effects were PAF-R-deficient.